Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10^th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025.

"Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye diseases. This milestone would not have been possible without the unrelenting dedication of our teams, the trust of our customers and steadfast support of our partners and shareholders," said Thomas Burns, Glaukos chairman and chief executive officer. "Over the past decade, Glaukos has grown from a single-product, U.S.-focused company into a diversified, global leader in ophthalmology, now with more than 1,000 employees around the world. Just as it did at the time of our IPO, innovation remains at the core of everything we do. I am deeply grateful for how far we've come, and excited as we embark upon our next transformational decade ahead."

Coverage of the NYSE Closing Bell will be live streamed and on replay on the NYSE website at https://www.nyse.com/bell, and may also be viewed on various media outlets such as CNBC.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose^® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250625995676/en/

Investor Contact:

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Media Contact:

Andria Arena

aarena@jpa.com

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell